Cytek Biosciences Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $53.229M Beat $52.800M Estimate
Benzinga Newsdesk 5 hours ago
NewsEarningsEarnings Beats
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 25 percent decrease over losses of $(0.04) per share from
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 25 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $53.229 million which beat the analyst consensus estimate of $52.800 million by 0.81 percent. This is a 1.79 percent increase over sales of $52.293 million the same period last year.